Evidence map›Paper›PMID 33230218›Full record

ArticleScientific reports2020

The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine.

Shan-Ming Chen, Wee-Wei Chieng, Szu-Wei Huang, Li-Jin Hsu, Ming-Shiou Jan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 90 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Shan-Ming ChenDepartment of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan.
Wee-Wei ChiengInstitute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung, Taiwan.
Szu-Wei HuangDepartment of Post-Baccalaureate Veterinary Medicine, Asia University, Taichung, Taiwan.
Li-Jin HsuDepartment of Medical Laboratory Science and Technology, Medical College, National Cheng Kung University, Tainan, Taiwan.
Ming-Shiou JanInstitute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung, Taiwan. msjan@csmu.edu.tw.
Chung Shan Medical University · TWAsia University · TWNational Cheng Kung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is one of the most lethal and chemo-resistant cancers worldwide. Growing evidence supports the theory that the gut microbiota plays an essential role in modulating the host response to anti-cancer therapy. The present study aimed to explore the effect of probiotics as an adjuvant during chemotherapy for pancreatic cancer. An LSL-Kras

Indexed as

LactobacillusAdministration, OralAnimalsAntimetabolites, AntineoplasticCarcinoma, Pancreatic DuctalCeruletideDeoxycytidineDisease Models, AnimalFemaleGastrointestinal MicrobiomeGemcitabineInjections, IntraperitonealMaleMiceMice, Inbred C57BLMice, TransgenicAntimetabolites, AntineoplasticCeruletideDeoxycytidineGemcitabine

Identifiers

PMID33230218
PMCPMC7683550
OpenAlexW3106927743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.